Abstract:6028 Background: The role of a triple combination of gemcitabine (chemotherapy) plus apatinib (anti-VEGF) and toripalimab (anti-PD-1) (GAT) in recurrent/metastatic nasopharyngeal carcinoma is unclear. Methods: Between August 2019 and April 2020, 54 patients with recurrent or metastatic NPC were screened, of whom 41 eligible patients were enrolled and received study treatment. Patients were treated with gemcitabine (1000 mg/m 2 ) on days 1 and 8 once every 3 weeks for a maximum of 6 cycles plus toripalimab (240 mg) on day 1 once every 3 weeks and apatinib (orally administered at 250 mg) once a day until disease progression, death, dose-limiting toxicities, or at the patient’s request to stop. The primary endpoint was the safety. The secondary endpoints included the objective response rate (ORR) and progression-free survival (PFS). Results: By the data cutoff date, the median follow-up time was 13.4 months. G3-4 hematologic, gastrointestinal and kidney toxicities were observed in no more than 3 (3/41, 7.3%) patients, while G3-4 nasopharyngeal wall necrosis was observed in 9 (9/41, 21.9%) patients. High-risk factors for nasopharyngeal necrosis, included repeated radiotherapy and an interval of less than 12 months from the last radiotherapy. Among all 41 patients, the ORR was 90.2% (95% CI: 76.9%-97.2%). The median PFS was 13.93 months (95% CI: NR-NR), and the 12-month PFS rate was 72.0% (95% CI: 57.1%-86.9%). A substantial increase of CD28+ and ICOS+ CD4+/CD8+ T cells and a decrease of PD1+ CD4+/CD8+ T cells were observed in the peripheral blood after the GAT treatment. 11q13.3 amplification and MRGPRF high expression in tumors correlated with poor PFS from the triple combination therapy. NPCs with 11q13.3 amplification was characterized by high epithelial mesenchymal transition (EMT) and immune suppressive transcriptional signatures. Furthermore, serial circulating tumor DNA (ctDNA) sequencing could predict PFS outcomes to combination therapy. Conclusions: The triple combination of GAT exhibits a promising antitumor activity and manageable toxicities in patients with recurrent/metastatic NPC. Patients with repeated radiotherapy and an interval of less than 12 months from the last radiotherapy should be carefully selected for antiangiogenic therapies. An integrated genomic and transcriptional analyses may aid to identify the beneficial patient populations in response to this novel combination therapy. Clinical trial information: NCT04073784.

The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma

The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment

A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC

Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China

Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens

Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma

The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis

Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances The Efficacy Of The Gemcitabine Plus Cisplatin Chemotherapy Regimen For Metastatic Nasopharyngeal Carcinoma

Experience with Combination of Cisplatin Plus Gemcitabine Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Is Gemcitabine and Cisplatin Induction Chemotherapy Superior in Locoregionally Advanced Nasopharyngeal Carcinoma?

Gemcitabine Versus Docetaxel Plus Cisplatin as Induction Chemotherapy in Nasopharyngeal Carcinoma

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma

Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.

Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma

Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study

Gemcitabine/Cisplatin versus docetaxel, cisplatin and 5-fluorouracil as induction chemotherapy in locally advanced nasopharyngeal carcinoma

Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth

Gemcitabine And Cisplatin (Gp) Induction Chemotherapy (Ic) Plus Concurrent Chemoradiotherapy (Ccrt) Versus Ccrt Alone In Locoregionally Advanced Nasopharyngeal Carcinoma (Npc): A Phase 3, Multicenter, Randomized Controlled Trial.

Gemcitabine Based Induction Chemotherapy May Improve the Survival of Stage IVA Nasopharyngeal Carcinoma

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin

Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer